Search research articles
Contact Us
Filters
Showing results (191-200 of 460) with videos related to
Page
of 46
Sort By:
Bone Marrow Transplantation
|
April 22, 2018
Use of propylene glycol-free melphalan conditioning in light-chain amyloidosis patients undergoing autologous hematopoietic cell transplantation is well tolerated and effective
Talha Badar, Parameswaran Hari, Saurabh Chhabra, et al.
Hematology/Oncology and Stem Cell Therapy
|
December 27, 2011
Higher infused CD34+ cell dose and overall survival in patients undergoing in vivo T-cell depleted, but not t-cell repleted, allogeneic peripheral blood hematopoietic cell transplantation
Abraham Sebastian Kanate, Michael Craig, Aaron Cumpston, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners
|
August 31, 2015
Randomized controlled trials in relapsed/refractory follicular lymphoma: a systematic review and meta-analysis
Rachel L Police, Peter C Trask, Jianmin Wang, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
June 11, 2008
Addition of infliximab to standard acute graft-versus-host disease prophylaxis following allogeneic peripheral blood cell transplantation
Mehdi Hamadani, Craig C Hofmeister, Buffy Jansak, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
December 3, 2014
Randomized controlled trials in relapsed/refractory chronic lymphocytic leukemia: a systematic review and meta-analysis
Rachel L Police, Peter C Trask, Jianmin Wang, et al.
Ejhaem
|
February 26, 2024
In relapsed or refractory diffuse large B-cell lymphoma, CD19 expression by immunohistochemistry alone is not a predictor of response to loncastuximab tesirine
Paolo F Caimi, Mehdi Hamadani, Carmelo Carlo-Stella, et al.
British Journal of Haematology
|
October 13, 2024
Outcomes of frail patients undergoing high-dose chemotherapy and autologous stem cell transplantation for multiple myeloma
Stephanie Yohay, Temitope Oloyede, Soyoung Kim, et al.
Transplantation and Cellular Therapy
|
July 8, 2023
Updated Indications for Immune Effector Cell Therapy: 2023 Guidelines from the American Society for Transplantation and Cellular Therapy
Abraham S Kanate, Navneet Majhail, Zachariah DeFilipp, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
February 8, 2018
Survival of Lymphoma Patients Experiencing Relapse or Progression after an Allogeneic Hematopoietic Cell Transplantation
Narendranath Epperla, Mehdi Hamadani, Kwang W Ahn, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
January 18, 2012
Intermediate-dose versus low-dose cyclophosphamide and granulocyte colony-stimulating factor for peripheral blood stem cell mobilization in patients with multiple myeloma treated with novel induction therapies
Mehdi Hamadani, S Thomas Kochuparambil, Salman Osman, et al.
Page
of 46
Search research articles
Search
Showing results (191-200 of 460) with videos related to
Sort By:
Page
of 46
Bone Marrow Transplantation
|
April 22, 2018
Use of propylene glycol-free melphalan conditioning in light-chain amyloidosis patients undergoing autologous hematopoietic cell transplantation is well tolerated and effective
Talha Badar, Parameswaran Hari, Saurabh Chhabra, et al.
Hematology/Oncology and Stem Cell Therapy
|
December 27, 2011
Higher infused CD34+ cell dose and overall survival in patients undergoing in vivo T-cell depleted, but not t-cell repleted, allogeneic peripheral blood hematopoietic cell transplantation
Abraham Sebastian Kanate, Michael Craig, Aaron Cumpston, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners
|
August 31, 2015
Randomized controlled trials in relapsed/refractory follicular lymphoma: a systematic review and meta-analysis
Rachel L Police, Peter C Trask, Jianmin Wang, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
June 11, 2008
Addition of infliximab to standard acute graft-versus-host disease prophylaxis following allogeneic peripheral blood cell transplantation
Mehdi Hamadani, Craig C Hofmeister, Buffy Jansak, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
December 3, 2014
Randomized controlled trials in relapsed/refractory chronic lymphocytic leukemia: a systematic review and meta-analysis
Rachel L Police, Peter C Trask, Jianmin Wang, et al.
Ejhaem
|
February 26, 2024
In relapsed or refractory diffuse large B-cell lymphoma, CD19 expression by immunohistochemistry alone is not a predictor of response to loncastuximab tesirine
Paolo F Caimi, Mehdi Hamadani, Carmelo Carlo-Stella, et al.
British Journal of Haematology
|
October 13, 2024
Outcomes of frail patients undergoing high-dose chemotherapy and autologous stem cell transplantation for multiple myeloma
Stephanie Yohay, Temitope Oloyede, Soyoung Kim, et al.
Transplantation and Cellular Therapy
|
July 8, 2023
Updated Indications for Immune Effector Cell Therapy: 2023 Guidelines from the American Society for Transplantation and Cellular Therapy
Abraham S Kanate, Navneet Majhail, Zachariah DeFilipp, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
February 8, 2018
Survival of Lymphoma Patients Experiencing Relapse or Progression after an Allogeneic Hematopoietic Cell Transplantation
Narendranath Epperla, Mehdi Hamadani, Kwang W Ahn, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
January 18, 2012
Intermediate-dose versus low-dose cyclophosphamide and granulocyte colony-stimulating factor for peripheral blood stem cell mobilization in patients with multiple myeloma treated with novel induction therapies
Mehdi Hamadani, S Thomas Kochuparambil, Salman Osman, et al.
Page
of 46